AcouSort AB has recently made waves in the biopharmaceutical industry by securing a technology evaluation agreement with Danish diagnostics company SeeQ Diagnostics. This strategic collaboration aims to evaluate AcouSort’s cutting-edge blood/plasma separation technology for the seamless preparation of blood samples on SeeQ’s diagnostic platform, SepSeeQ.
The partnership is poised to revolutionize the diagnostic landscape, as highlighted by Dr. Torsten Freltoft, the CEO of AcouSort AB. Dr. Freltoft expressed great enthusiasm about the collaboration, emphasizing the potential for not only enhancing the SepSeeQ assay but also independently commercializing a pipetting robot interface tailored for blood/plasma separation in various plasma-based assays.
SeeQ Diagnostics, led by CEO Anders B. Sørensen, is at the forefront of developing the SepSeeQ diagnostic assay, designed to rapidly detect infectious microorganisms directly from minute plasma samples. By integrating AcouSort’s acoustic separation technology into their automated workflows, SeeQ aims to streamline the process from sample collection to pathogen identification. This efficiency boost is expected to empower healthcare providers to expedite antimicrobial treatments and enhance patient outcomes significantly.
The technology evaluation agreement between AcouSort and SeeQ Diagnostics encompasses the assessment of a versatile interface unit that can be mounted on a standard pipetting robot, along with AcouSort’s specialized Acoustic Separation modules engineered for blood/plasma separation. This comprehensive solution promises to optimize sample preparation procedures, paving the way for more efficient and accurate diagnostic testing.
A key aspect of the collaboration is the delineation of intellectual property rights. Any advancements related to the SepSeeQ assay will belong to SeeQ Diagnostics, while innovations pertaining to blood plasma preparation using AcouSort technology will be under the ownership of AcouSort, with a potential licensing arrangement for SeeQ Diagnostics. This strategic alignment ensures that both parties can leverage their respective strengths to drive innovation in the diagnostic field effectively.
Moreover, the collaboration extends to a joint venture with a prominent provider of advanced pipetting robot systems, enhancing the scope and impact of the partnership. By pooling their expertise and resources, the collaborators aim to accelerate the development and deployment of next-generation diagnostic solutions that can address critical healthcare challenges.
About SeeQ Diagnostics:
SeeQ Diagnostics, a dynamic Danish startup supported by the BioInnovation Institute in Copenhagen, is dedicated to revolutionizing precision diagnostics. Their flagship product, SepSeeQ, offers a rapid and precise method for identifying pathogens from minimal plasma samples within a remarkably short timeframe. With successful evaluations in various clinical settings and ongoing exploratory initiatives, SeeQ Diagnostics is poised to make significant contributions to the field of infectious disease diagnostics.
About AcouSort AB:
AcouSort AB is an innovative technology company that specializes in the development of products and solutions for integrated biological sample preparation. Leveraging the power of sound waves, AcouSort’s products can effectively separate blood cells, concentrate bioentities, and purify samples for a myriad of applications. The company’s acoustofluidics technology, which combines sound waves and microfluidics, enables automated sample handling across diverse research and diagnostic domains, including the development of Point-of-Care (POC) systems.
For further information about AcouSort, interested parties can reach out to CEO Torsten Freltoft via the provided contact details.
In conclusion, the collaboration between AcouSort AB and SeeQ Diagnostics marks a significant milestone in the realm of diagnostic innovation. By synergizing their expertise and technologies, the partners are poised to drive transformative advancements in sample preparation and diagnostic testing. This strategic alliance not only holds promise for enhancing existing diagnostic platforms but also paves the way for the development of novel solutions that can address critical healthcare needs effectively.
Key Takeaways:
– The collaboration between AcouSort AB and SeeQ Diagnostics aims to evaluate AcouSort’s blood/plasma separation technology for the SepSeeQ diagnostic platform.
– AcouSort’s innovative acoustic separation technology has the potential to streamline sample preparation processes and enhance diagnostic accuracy.
– Intellectual property rights are clearly defined in the technology evaluation agreement, ensuring equitable distribution of innovations.
– SeeQ Diagnostics’ SepSeeQ assay offers rapid pathogen detection from minimal plasma samples, revolutionizing infectious disease diagnostics.
– The partnership between AcouSort and SeeQ signifies a strategic alignment to drive innovation in precision diagnostics.
– By leveraging sound waves and microfluidics, AcouSort is at the forefront of developing automated sample preparation solutions for diverse applications.
Read more on <a href=”https://AcouSort AB has recently made waves in the biopharmaceutical industry by securing a technology evaluation agreement with Danish diagnostics company SeeQ Diagnostics. This strategic collaboration aims to evaluate AcouSort’s cutting-edge blood/plasma separation technology for the seamless preparation of blood samples on SeeQ’s diagnostic platform, SepSeeQ.
The partnership is poised to revolutionize the diagnostic landscape, as highlighted by Dr. Torsten Freltoft, the CEO of AcouSort AB. Dr. Freltoft expressed great enthusiasm about the collaboration, emphasizing the potential for not only enhancing the SepSeeQ assay but also independently commercializing a pipetting robot interface tailored for blood/plasma separation in various plasma-based assays.
SeeQ Diagnostics, led by CEO Anders B. Sørensen, is at the forefront of developing the SepSeeQ diagnostic assay, designed to rapidly detect infectious microorganisms directly from minute plasma samples. By integrating AcouSort’s acoustic separation technology into their automated workflows, SeeQ aims to streamline the process from sample collection to pathogen identification. This efficiency boost is expected to empower healthcare providers to expedite antimicrobial treatments and enhance patient outcomes significantly.
The technology evaluation agreement between AcouSort and SeeQ Diagnostics encompasses the assessment of a versatile interface unit that can be mounted on a standard pipetting robot, along with AcouSort’s specialized Acoustic Separation modules engineered for blood/plasma separation. This comprehensive solution promises to optimize sample preparation procedures, paving the way for more efficient and accurate diagnostic testing.
A key aspect of the collaboration is the delineation of intellectual property rights. Any advancements related to the SepSeeQ assay will belong to SeeQ Diagnostics, while innovations pertaining to blood plasma preparation using AcouSort technology will be under the ownership of AcouSort, with a potential licensing arrangement for SeeQ Diagnostics. This strategic alignment ensures that both parties can leverage their respective strengths to drive innovation in the diagnostic field effectively.
Moreover, the collaboration extends to a joint venture with a prominent provider of advanced pipetting robot systems, enhancing the scope and impact of the partnership. By pooling their expertise and resources, the collaborators aim to accelerate the development and deployment of next-generation diagnostic solutions that can address critical healthcare challenges.
About SeeQ Diagnostics:
SeeQ Diagnostics, a dynamic Danish startup supported by the BioInnovation Institute in Copenhagen, is dedicated to revolutionizing precision diagnostics. Their flagship product, SepSeeQ, offers a rapid and precise method for identifying pathogens from minimal plasma samples within a remarkably short timeframe. With successful evaluations in various clinical settings and ongoing exploratory initiatives, SeeQ Diagnostics is poised to make significant contributions to the field of infectious disease diagnostics.
About AcouSort AB:
AcouSort AB is an innovative technology company that specializes in the development of products and solutions for integrated biological sample preparation. Leveraging the power of sound waves, AcouSort’s products can effectively separate blood cells, concentrate bioentities, and purify samples for a myriad of applications. The company’s acoustofluidics technology, which combines sound waves and microfluidics, enables automated sample handling across diverse research and diagnostic domains, including the development of Point-of-Care (POC) systems.
For further information about AcouSort, interested parties can reach out to CEO Torsten Freltoft via the provided contact details.
In conclusion, the collaboration between AcouSort AB and SeeQ Diagnostics marks a significant milestone in the realm of diagnostic innovation. By synergizing their expertise and technologies, the partners are poised to drive transformative advancements in sample preparation and diagnostic testing. This strategic alliance not only holds promise for enhancing existing diagnostic platforms but also paves the way for the development of novel solutions that can address critical healthcare needs effectively.
Key Takeaways:
– The collaboration between AcouSort AB and SeeQ Diagnostics aims to evaluate AcouSort’s blood/plasma separation technology for the SepSeeQ diagnostic platform.
– AcouSort’s innovative acoustic separation technology has the potential to streamline sample preparation processes and enhance diagnostic accuracy.
– Intellectual property rights are clearly defined in the technology evaluation agreement, ensuring equitable distribution of innovations.
– SeeQ Diagnostics’ SepSeeQ assay offers rapid pathogen detection from minimal plasma samples, revolutionizing infectious disease diagnostics.
– The partnership between AcouSort and SeeQ signifies a strategic alignment to drive innovation in precision diagnostics.
– By leveraging sound waves and microfluidics, AcouSort is at the forefront of developing automated sample preparation solutions for diverse applications.” target=”_blank” rel=”noopener”>AcouSort AB has recently made waves in the biopharmaceutical industry by securing a technology evaluation agreement with Danish diagnostics company SeeQ Diagnostics. This strategic collaboration aims to evaluate AcouSort’s cutting-edge blood